Table 5.
Delphi round 1 responses: indications for initiating osteoporosis-specific treatment
| Indications | Selected (n) | Consensus (% rating as extremely or very important, i.e., ≥ 75%) | |
|---|---|---|---|
| Yes | No | ||
| Hip fracture | 24 | 1 | Yes (96%) |
| Vertebral fracture | 24 | 1 | Yes (96%) |
| Non-hip non-vertebral fracture | 20 | 5 | Yes (80%) |
| BMD T-score ≤ − 2.5 SD | 18 | 7 | No |
| Osteopenia + FRAX® ≥ 3% hip or ≥ 20% MOF | 11 | 14 | No |
| Osteopenia + RFs or eligible by OSTA or SCORE | 7 | 18 | No |
| Osteopenia + ≥ 10 years post menopause | 3 | 23 | No |
| FRAX® or Garvan ≥ 3% hip or ≥ 20% MOF | 9 | 16 | No |
| Eligible by OSTA, MORES, or SCORE | 1 | 24 | No |
| QCT | 2 | 23 | No |
| Height loss > 4 cm | 11 | 14 | No |
| Androgen deprivation therapy | 10 | 6 | No |
| Aromatase inhibitor treatment | 9 | 16 | No |
| Glucocorticoid treatment | 17 | 8 | No |
| Country-specific thresholds | 14 | 11 | No |
BMD bone mineral density, MORES Male Osteoporosis Risk Estimation Score, OSTA Self-Assessment Tool for Asians, SCORE Simple Calculated Osteoporosis Risk Estimation, QCT quantitative computed tomography
The percentage of APCO member respondents who rated each of the proposed indications for initiating osteoporosis treatment identified in existing clinical practice guidelines, as extremely or very important for inclusion in APCO clinical practice standard 9